AB0589 TOCILIZUMAB FOR GIANT CELL ARTERITIS: BASELINE AND TWELVE MONTH AUDIT DATA FROM THE UK BRISTOL AND BATH MULTIDISCIPLINARY MEETING

Autor: C. N. R. Jayatilleke, A. Anilkumar, S. Janagan, R. W. Marshall, S. Skeoch, C. Guly, F. E. Sin, K. Austin, L. Al-Sweedan, A. Bourn, L. Clarke, H. Gunawardena, B. Boyce, S. Knights, J. D. Pauling, E. Reilly, T. D. Reynolds, S. Villar, J. C. Robson

Publikováno v: Annals of the Rheumatic Diseases. 81:1420.2-1421

BackgroundGiant Cell Arteritis (GCA) is a systemic vasculitis involving large and medium-sized blood vessels. Treatment is with high dose glucocorticoids. Steroid-sparing agents and Tocilizumab (TCZ) are used for refractory or relapsing cases. NHS En

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c31769cbd1420ebec95d1ff1dff8c532
https://doi.org/10.1136/annrheumdis-2022-eular.2872

A case of multicentric carcinoid in a patient with psoriatic spondyloarthropathy.

Autor: George N; North Central Thames Foundation School, London NW3 2P, UK., Depala A; North Central Thames Foundation School, London NW3 2P, UK., Al Sweedan L; George Eliot Hospital NHS Trust, Nuneaton CV10 7DJ, UK., Chakravarty K; Royal Free Hospital NHS Foundation Trust, London NW3 2QG, UK ; Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

Publikováno v: Case reports in rheumatology [Case Rep Rheumatol] 2015; Vol. 2015, pp. 179696. Date of Electronic Publication: 2015 Feb 23.